Clinical trial readout dates for PTC Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is September 2027.
| Phase 2 PTC844 Rheumatoid Arthritis · NCT07779616 | September 2027 Recruiting |
| Phase 3 Vatiquinone Friedreich Ataxia · NCT05515536 | December 2027 Ongoing |
| Phase 3 Vatiquinone Friedreich's Ataxia · NCT07681713 | March 2029 Not Yet Recruiting |
| Phase 3 Sepiapterin Phenylketonuria · NCT06302348 | February 2031 Recruiting |
PTC Therapeutics Inc. reported $2.09B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $52M.
| 8-K Other Events — often topline trial data | 2026-11-03 |
| 8-K Reg FD Disclosure — often a data announcement | 2026-10-29 |